Market Report, "Neogenix Oncology, Inc. - Product Pipeline Review - 2012", Published

New Pharmaceuticals market report from Global Markets Direct: "Neogenix Oncology, Inc. - Product Pipeline Review - 2012"


Boston, MA -- (SBWire) -- 12/24/2012 --Global Market Direct's pharmaceuticals report, "Neogenix Oncology, Inc. - Product Pipeline Review - 2012" provides data on the Neogenix Oncology, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Neogenix Oncology, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Neogenix Oncology, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents


- Neogenix Oncology, Inc. - Brief Neogenix Oncology, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Neogenix Oncology, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Neogenix Oncology, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Neogenix Oncology, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to Get this Report

- Evaluate Neogenix Oncology, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Neogenix Oncology, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Neogenix Oncology, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Neogenix Oncology, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Neogenix Oncology, Inc. and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- ZIOPHARM Oncology, Inc. - Product Pipeline Review - 2012
- Sentinel Oncology Limited - Product Pipeline Review - 2012
- Gastrointestinal Tract Cancer - Pipeline Review, H2 2012
- Pancreatic Cancer - Pipeline Review, H1 2012
- Cervical Cancer - Pipeline Review, H1 2012
- Ovarian Cancer - Pipeline Review, H2 2012
- Hepatocellular Carcinoma - Pipeline Review, H1 2012
- Peritoneal Cancer - Pipeline Review, H1 2012
- Breast Cancer - Pipeline Review, H2 2012
- Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Media Relations Contact

Bill Thompson
Director of Marketing

View this press release online at: